PHARMARON (03759) has issued an announcement addressing recent media reports concerning a production collaboration between the Group and a Chinese subsidiary of an internationally leading pharmaceutical enterprise. Following reasonable inquiries under the circumstances, the company confirms that the aforementioned production cooperation was established and will be conducted as part of the Group's ordinary and usual business operations. In the course of its daily operations, the Group routinely engages in collaborations with multiple companies across different fields to further its own business development goals. Furthermore, the company is not aware of any information that must be disclosed to prevent a false market in the company's securities, nor is it aware of any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).